Exec-Edge – Page 93 – ExecEdge

Dutch Bros 1Q Sales Surge 30%, Company Reaffirms 2023 Guidance

Dutch Bros 1Q Sales Surge 30%, Company Reaffirms 2023 Guidance

By Exec Edge Editorial Staff Dutch Bros Inc. (NYSE: BROS) coffee chain reported a 30% rise in first quarter sales and reiterated its full-year guidance. Joth Ricci, Chief Executive Officer of Dutch Bros, stated, “We also saw meaningful margin expansion,...

Portillo’s First Quarter Revenue Climbs 16% on New Restaurants

Portillo’s First Quarter Revenue Climbs 16% on New Restaurants

By Exec Edge Editorial Staff Chicago-style fast-casual chain Portillo’s (Nasdaq: PTLO) said revenue rose 16%  to $156.1 million in the first quarter. Portillo’s will open nine new restaurants in 2023, with an emphasis on the Sun Belt, it said. The chain opened...

Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis

Eterna Therapeutics Buys Allogeneic Immuno-Oncology Platform from Exacis

  By Healthcare Edge Editorial Staff Eterna Therapeutics Inc. (Nasdaq: ERNA) said it has acquired Exacis Biotherapeutics’ global immuno-oncology platform, which includes their pipeline of engineered cell therapy programs for hematologic and solid tumors. The acquisition gives Eterna an exclusive global license...

Input your search keywords and press Enter.